Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Altered regional cerebral function and its association with cognitive impairment in COVID‑19: A prospective FDG PET study

Ganna Blazhenets, Nils Schroeter, Tobias Bormann, Johannes Thurow, Dirk Wagner, Lars Frings, Cornelius Weiller, Andrea Dressing, Jonas Hosp and Philipp Meyer
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 41;
Ganna Blazhenets
1Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nils Schroeter
2Department of Neurology and Clinical Neuroscience, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Bormann
2Department of Neurology and Clinical Neuroscience, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Thurow
1Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Wagner
3Department of Internal Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Frings
1Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelius Weiller
2Department of Neurology and Clinical Neuroscience, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Dressing
2Department of Neurology and Clinical Neuroscience, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Hosp
2Department of Neurology and Clinical Neuroscience, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Meyer
1Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

41

Objectives: Given the rapid spread of SARS-CoV-2 and emerging evidence of neurological symptoms particularly in hospitalized COVID-19 patients, we prospectively examined the impact of COVID‑19 on the CNS in inpatients at the subacute and the chronic stage by FDG PET and neurological examination.

Methods: We assessed neurological and neuropsychological symptoms (Montreal Cognitive Assessment, MoCA, adjusted for years of education) and FDG PET scans in 15 COVID-19 inpatients with at least one new neurological symptom at the subacute stage (once were no longer infectious). All scans were visually read using a 3-step rating scale (normal, mildly and severely abnormal). Principal components analysis (PCA; avoiding the need of a currently unknown reference region) was employed to explore whether a spatial covariance pattern exists in COVID-19 (compared to 45 control patients without somatic CNS disease). In eight of these patients, we re-assessed FDG PET and MoCA performance at the chronic stage approximately six months after symptom onset to examine the time course of post-COVID-19 cognitive impairment. For further validation, we also conducted a conventional group analysis using statistical parametric mapping (SPM) and a white matter as reference region (given the obvious involvement of grey matter in visual analysis).

Results: 29 of 41 screened inpatients showed one or more new neurological symptoms and gave written informed consent. Initial hospitalization was done because of medical, not neurological complications; only 2 patients underwent ICU treatment. 18 of 26 (69%, 3 refused) patients showed cognitive impairment defined as MoCA≤26. 15 patients also agreed to undergo FDG PET. Visual reads indicated pathological results (mainly frontoparietal hypometabolism) in 10/15 patients at the subacute stage. We detected a highly significant (p<0.001) COVID-19-related spatial covariance pattern characterized by positive weights in brain stem, cerebellum, white matter and mesiotemporal structures and negative weights in wide-spread neocortical areas (with frontoparietal predominance). Visual reads correlated significantly with the individual pattern expression score (PES) of the COVID‑19‑related pattern (r=0.80, p<0.001) and we found a highly significant linear relationship between MoCA and the PES at the subacute stage (R2=0.62, p<0.001). Conventional SPM analysis also showed wide-spread, frontoparietal dominant neocortical hypometabolism whereas there were no hypermetabolic clusters (false discovery rate [FDR]‑corrected p<0.01). In the eight COVID-19 patients presented for a follow-up, the mean PES at the chronic stage was significantly lower compared to the subacute stage (two-tailed paired t test, p=0.002), but still at trend-level higher in comparison to the control group (one-tailed two-sample t test, p=0.06). In parallel, MoCA significantly improved from 19.1±4.5 at the subacute stage to 23.4±3.6 at the chronic stage (p<0.05), which was however still below normal in 5/8 patients. Group analysis using SPM also showed a wide-spread increase of normalized FDG uptake in frontoparietal and, to a lesser extent, temporal neocortical regions at the chronic stage compared to the subacute stage (FDR‑corrected p<0.01). At an exploratory statistical threshold (p<0.005), there was also a remaining neocortical hypometabolism in COVID-19 patients at the chronic stage compared to the control group.

Conclusions: Neocortical dysfunction accompanied by cognitive impairment was detected in two-thirds of inpatients with subacute COVID-19. Although a significant recovery of regional neuronal function and cognition can be clearly stated, residuals are still measurable in some patients six month after manifestation of COVID-19. In consequence, post-COVID-19 patients with persistent cognitive complaints should be presented to a neurologist and possibly allocated to cognitive rehabilitation programs.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Altered regional cerebral function and its association with cognitive impairment in COVID‑19: A prospective FDG PET study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Altered regional cerebral function and its association with cognitive impairment in COVID‑19: A prospective FDG PET study
Ganna Blazhenets, Nils Schroeter, Tobias Bormann, Johannes Thurow, Dirk Wagner, Lars Frings, Cornelius Weiller, Andrea Dressing, Jonas Hosp, Philipp Meyer
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 41;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Altered regional cerebral function and its association with cognitive impairment in COVID‑19: A prospective FDG PET study
Ganna Blazhenets, Nils Schroeter, Tobias Bormann, Johannes Thurow, Dirk Wagner, Lars Frings, Cornelius Weiller, Andrea Dressing, Jonas Hosp, Philipp Meyer
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 41;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • The value of 18F-FDG PET in the diagnostic workup of pediatric fever of unknown origin: a systematic review and meta-analysis
  • Prediction of absorbed dose by tumors and critical organs after Lu-177-DOTATATE therapy using pretherapeutic Ga-68-DOTATOC PET/CT
  • Feasibility of imaging synaptic density in the human spinal cord using 11C-UCB-J PET
Show more Oral - PhysicianPharm

Neurosciences Young Investigator Award Session

  • In-vivo tau pathology is associated with synaptic loss and altered synaptic function
  • Neurofibrillary tau emerges in adults with Down syndrome during the earliest stages of Aβ accumulation
  • In vivo comparison of three novel radiotracers for the NMDA receptor GluN2B subunit in non-human primates
Show more Neurosciences Young Investigator Award Session

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire